The Roche radioimmunoconjugate RO5429083 (RG7356) antibody targets a conformational-dependent epitope of CD44 (in the constant region of the extracellular domain), and it is being tested in clinical trials to treat neoplasms (NCT01358903) and acute myelogenous leukemia (NCT01641250) (197, 198). The gene discussed is CD44; the disease is neoplasm.